Compare Davita Inc (DVA) vs Herbalife Nutrition Ltd (HLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Herbalife Nutrition Ltd — how do they compare? Davita Inc trades at $179.44 (market cap $11.29B), while Herbalife Nutrition Ltd trades at $12.89 (market cap $1.34B). The key difference: Davita Inc is far larger — about 8.4× Herbalife Nutrition Ltd's market cap, and Davita Inc is trading nearer its 52-week high, Herbalife Nutrition Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Herbalife Nutrition Ltd for 43 Days on average.
| DVA | HLF | |
|---|---|---|
Market Cap | $11.29B | $1.34B |
Volume | 582,204 | 1,589,457 |
Sector | Health | Consumer Staples |
52-Week High | $240.96 | $19.96 |
52-Week Low | $103.87 | $7.75 |
Typical Hold Time | 113 Days | 43 Days |
Enterprise Value | $24.01B | $3.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, with a bearish technical signal and neutral oscillators. The company shows strong earnings beats in recent quarters with Q2 2026 EPS of $4.02 beating expectations of $3.88. Revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026, though net margins have fluctuated. Recent partnership expansion with Humana for value-based kidney care represents significant business development.
DVA presents a mixed outlook with 43% analyst buy ratings and a $235.67 price target suggesting 33% upside. However, high debt levels (65.55% debt-to-asset ratio) and regulatory risks in healthcare weigh on fundamentals. The stock's current valuation at P/E 15 and P/S 0.88 appears reasonable relative to earnings growth potential, making it attractive for value investors despite near-term bearish technicals.
HLF trades at $12.65, up 0.56% today, with a bullish technical signal from moving averages. The stock shows attractive valuation with a P/E of 8.22 and P/S of 0.26. Recent earnings were mixed, with a Q1 2026 beat but Q4 2025 and Q2 2026 misses. The company announced a $250 million share repurchase program and a CEO transition effective October 31, 2026. Cash flow trends show improvement, with 2026 projected net cash flow turning positive at $50 million.
The outlook is cautiously optimistic, supported by analyst consensus price target of $19.00 implying significant upside. Key opportunities include debt reduction progress and margin expansion plans. Risks include inconsistent earnings performance, high debt levels, and investor scrutiny following the CEO transition. The stock remains a value play if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Herbalife Nutrition Ltd
Herbalife Nutrition Ltd is an international nutrition company.
Read more on HLF →
